Natural killer cells acquire CD73 expression upon exposure to mesenchymal stem cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

38 citing papers in PubMed.

1. Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells.Cell & bioscience · 2025
   Review
2. Therapeutic potential of CD73Histology and histopathology · 2025
   Review
3. CD73/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies.Frontiers in cell and developmental biology · 2024
   Review
4. Adenosine metabolism by mesenchymal stromal cells isolated from different human tissues.Human cell · 2023
   Article
5. Unlocking antitumor immunity with adenosine receptor blockers.Cancer drug resistance (Alhambra, Calif.) · 2023
   Review
6. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.Frontiers in immunology · 2023
   Review
7. Functional expression of CD73 on human natural killer cells.Cancer immunology, immunotherapy : CII · 2022
   Article
8. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.Frontiers in immunology · 2022
   Article
9. SDF-1Stem cells international · 2021
   Article
10. From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Immunological Considerations.Frontiers in immunology · 2021
    Review
11. Potential of Extracellular Vesicle-Associated TSG-6 from Adipose Mesenchymal Stromal Cells in Traumatic Brain Injury.International journal of molecular sciences · 2020
    Review
12. Immortalization of Mesenchymal Stromal Cells by TERT Affects Adenosine Metabolism and Impairs their Immunosuppressive Capacity.Stem cell reviews and reports · 2020
    Article
13. Targeting CD73 to augment cancer immunotherapy.Current opinion in pharmacology · 2020
    Review
14. Reversible Growth-Arrest of a Spontaneously-Derived Human MSC-Like Cell Line.International journal of molecular sciences · 2020
    Article
15. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy.Cellular and molecular life sciences : CMLS · 2020
    Review
16. Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies.Cells · 2020
    Review
17. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.The Journal of clinical investigation · 2020
    Article
18. Immune modulation by mesenchymal stem cells.Cell proliferation · 2020
    Review
19. Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection.Turkish journal of biology = Turk biyoloji dergisi · 2020
    Article
20. Kinetics of MSC-based enzyme therapy for immunoregulation.Journal of translational medicine · 2019
    Article

Corrections and comments

• Comment on
  Adenosine production by human B cells and B cell-mediated suppression of activated T cells.2013

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as